
Vanda Pharmaceuticals Inc.: shareholders and insiders
Price
$3.44
November 20, 2026Market cap $204M
What Ploutos Investor adds for Vanda Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Nov 5, 2026, from their own Form 4 filings.
Bought on the market
$38.1K
1 person
Sold on the market
$2.8M
6 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $38.1K by 1 person·sold $2.8M by 6 people
- 2025: no buys, no sales
- 2026: bought $38.1K by 1 person, sold $2.8M by 6 people
- Nov 5, 2026Charles Cliff DuncanDirectorKind
- Nov 4, 2026Charles Cliff DuncanDirectorKind
- Nov 3, 2026Charles Cliff DuncanDirectorKind
- Jun 4, 2026Daniel Patrick McGuireSVP, GC and SecretaryKind
- Jun 4, 2026Phaedra ChrousosDirectorKind
- Jun 4, 2026Charles Cliff DuncanDirectorKind
- Jun 4, 2026Richard W DuganDirectorKind
- Jun 4, 2026Anne Sempowski WardDirectorKind
- Jun 4, 2026Tage HonoreDirectorKind
- Jun 4, 2026Stephen Ray MitchellDirectorKind
- Mar 2, 2026Mihael Hristos PolymeropoulosPresident and CEOKind
- Mar 2, 2026Gunther BirznieksSVP, Business DevelopmentKind
- Mar 2, 2026Timothy WilliamsSVP & General CounselKind
- Mar 2, 2026Joakim WijkstromSVP, Chief Marketing OfficerKind
- Mar 2, 2026Kevin Patrick MoranSVP, CFO & TreasurerKind
- Feb 23, 2026Tage HonoreKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | Charles Cliff DuncanDirector | 5,803 | $3.80 | $22.1K | Form 4 | |
| Nov 4, 2026 | Charles Cliff DuncanDirector | 3,447 | $3.82 | $13.2K | Form 4 | |
| Nov 3, 2026 | Charles Cliff DuncanDirector | 750 | $3.80 | $2.8K | Form 4 | |
| Jun 4, 2026 | Daniel Patrick McGuireSVP, GC and Secretary | 80.0K | – | – | Form 4 | |
| Jun 4, 2026 | Phaedra ChrousosDirector | 41.6K | – | – | Form 4 | |
| Jun 4, 2026 | Charles Cliff DuncanDirector | 41.6K | – | – | Form 4 | |
| Jun 4, 2026 | Richard W DuganDirector | 41.6K | – | – | Form 4 | |
| Jun 4, 2026 | Anne Sempowski WardDirector | 41.6K | – | – | Form 4 | |
| Jun 4, 2026 | Tage HonoreDirector | 41.6K | – | – | Form 4 | |
| Jun 4, 2026 | Stephen Ray MitchellDirector | 41.6K | – | – | Form 4 | |
| Mar 2, 2026 | Mihael Hristos PolymeropoulosPresident and CEO | 156.2K | $8.17 | $1.3M | Form 4 | |
| Mar 2, 2026 | Gunther BirznieksSVP, Business Development | 42.4K | $8.27 | $350.9K | Form 4 | |
| Mar 2, 2026 | Timothy WilliamsSVP & General Counsel | 42.4K | $8.27 | $350.9K | Form 4 | |
| Mar 2, 2026 | Joakim WijkstromSVP, Chief Marketing Officer | 30.8K | $8.27 | $254.7K | Form 4 | |
| Mar 2, 2026 | Kevin Patrick MoranSVP, CFO & Treasurer | 42.4K | $8.27 | $351.0K | Form 4 | |
| Feb 23, 2026 | Tage Honore | 30.0K | $8.03 | $240.9K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 8, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by VNDA's officers and directors from 2006 up to November 20, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class8.10%
- Millennium Management LLCwith 2 more personsShare of class7.00%
- BlackRock Portfolio Management LLCShare of class5.90%
- AQR Capital Management, LLCwith 1 more personShare of class5.82%
- State StreetShare of class5.00%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.10% | 4.70M | Feb 7, 20252 filings since Feb 5, 2025 | 13G/A | |
| Millennium Management LLCwith 2 more persons | 7.00% | 4.26M | Oct 9, 20264 filings since Jul 1, 2025 | 13G/A | |
| BlackRock Portfolio Management LLC | 5.90% | 3.59M | Oct 27, 20264 filings since Apr 15, 2025 | 13G | |
| AQR Capital Management, LLCwith 1 more person | 5.82% | 3.50M | Aug 13, 2026 | 13G | |
| State Street | 5.00% | 3.01M | Nov 10, 20262 filings since May 12, 2026 | 13G |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- The Vanguard Group0.00%Mar 27, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter+166%
- Renaissance TechnologiesIn the quarter-3.9%
- Point72 (Cohen)In the quarter-67%
- Citadel Advisors (Griffin)In the quarter-90%
- D.E. ShawIn the quarter
- AQR CapitalIn the quarter-40%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | 4.26M | +166% | $21M | 0.02% |
| Renaissance Technologies | 3.31M | -3.9% | $16M | 0.02% |
| Point72 (Cohen) | 102.4K | -67% | $500.0K | 0.00% |
| Citadel Advisors (Griffin) | 74.0K | -90% | $400.0K | 0.00% |
| D.E. Shaw | 33.4K | $200.0K | 0.00% | |
| AQR Capital | 2.10M | -40% | $10M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 14.1% of its shares outstanding were held short, +6.1% since the report before.
- Shares held short
- 8.31M
- 14.1%
- Since the report before7.83M on Sep 30, 2026
- +6.1%
- 8.3
- 1.00M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 85%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 1.68M
- Nov 15, 2023: Shares held short 2.04M
- Nov 30, 2023: Shares held short 2.07M
- Dec 15, 2023: Shares held short 1.90M
- Dec 29, 2023: Shares held short 1.73M
- Jan 12, 2024: Shares held short 1.75M
- Jan 31, 2024: Shares held short 2.29M
- Feb 15, 2024: Shares held short 2.96M
- Feb 29, 2024: Shares held short 3.24M
- Mar 15, 2024: Shares held short 3.00M
- Mar 28, 2024: Shares held short 2.49M
- Apr 15, 2024: Shares held short 2.07M
- Apr 30, 2024: Shares held short 2.30M
- May 15, 2024: Shares held short 2.80M
- May 31, 2024: Shares held short 2.49M
- Jun 14, 2024: Shares held short 2.84M
- Jun 28, 2024: Shares held short 2.86M
- Jul 15, 2024: Shares held short 2.79M
- Jul 31, 2024: Shares held short 2.78M
- Aug 15, 2024: Shares held short 3.15M
- Aug 30, 2024: Shares held short 3.31M
- Sep 13, 2024: Shares held short 3.35M
- Sep 30, 2024: Shares held short 3.40M
- Oct 15, 2024: Shares held short 3.98M
- Oct 31, 2024: Shares held short 3.74M
- Nov 15, 2024: Shares held short 3.22M
- Nov 29, 2024: Shares held short 3.09M
- Dec 13, 2024: Shares held short 3.14M
- Dec 31, 2024: Shares held short 3.20M
- Jan 15, 2025: Shares held short 3.29M
- Jan 31, 2025: Shares held short 3.74M
- Feb 14, 2025: Shares held short 3.72M
- Feb 28, 2025: Shares held short 3.28M
- Mar 14, 2025: Shares held short 3.56M
- Mar 31, 2025: Shares held short 4.02M
- Apr 15, 2025: Shares held short 4.88M
- Apr 30, 2025: Shares held short 4.66M
- May 15, 2025: Shares held short 4.87M
- May 30, 2025: Shares held short 4.76M
- Jun 13, 2025: Shares held short 4.73M
- Jun 30, 2025: Shares held short 4.69M
- Jul 15, 2025: Shares held short 4.59M
- Jul 31, 2025: Shares held short 4.53M
- Aug 15, 2025: Shares held short 4.61M
- Aug 29, 2025: Shares held short 4.65M
- Sep 15, 2025: Shares held short 4.61M
- Sep 30, 2025: Shares held short 3.67M
- Oct 15, 2025: Shares held short 3.82M
- Oct 31, 2025: Shares held short 3.98M
- Nov 14, 2025: Shares held short 3.88M
- Nov 28, 2025: Shares held short 4.64M
- Dec 15, 2025: Shares held short 4.89M
- Dec 31, 2025: Shares held short 2.34M
- Jan 15, 2026: Shares held short 2.88M
- Jan 30, 2026: Shares held short 3.22M
- Feb 13, 2026: Shares held short 3.47M
- Feb 27, 2026: Shares held short 4.35M
- Mar 13, 2026: Shares held short 3.20M
- Mar 31, 2026: Shares held short 5.31M
- Apr 15, 2026: Shares held short 5.60M
- Apr 30, 2026: Shares held short 6.20M
- May 15, 2026: Shares held short 6.37M
- May 29, 2026: Shares held short 6.81M
- Jun 15, 2026: Shares held short 6.99M
- Jun 30, 2026: Shares held short 7.34M
- Jul 15, 2026: Shares held short 7.19M
- Jul 31, 2026: Shares held short 7.42M
- Aug 14, 2026: Shares held short 7.67M
- Aug 31, 2026: Shares held short 7.69M
- Sep 15, 2026: Shares held short 8.50M
- Sep 30, 2026: Shares held short 7.83M
- Oct 15, 2026: Shares held short 8.31M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading54.6% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 54.6% of the shares in the reported trades were short sales, against 51.5% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 54.6%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 51.5%
- Change
- +3.1 pts
- Short sales a dayon average, of 472.8K shares
- 258.0K
- More than atof 3,666 US-listed companies, same days
- 65%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 62.3%
- Oct 15, 2026: Short sales 54.8%
- Oct 16, 2026: Short sales 56.2%
- Oct 19, 2026: Short sales 65.4%
- Oct 20, 2026: Short sales 73.1%
- Oct 21, 2026: Short sales 49.3%
- Oct 22, 2026: Short sales 41.8%
- Oct 23, 2026: Short sales 71.5%
- Oct 26, 2026: Short sales 55.8%
- Oct 27, 2026: Short sales 40.7%
- Oct 28, 2026: Short sales 31.8%
- Oct 29, 2026: Short sales 44%
- Oct 30, 2026: Short sales 55%
- Nov 2, 2026: Short sales 55.4%
- Nov 3, 2026: Short sales 62.8%
- Nov 4, 2026: Short sales 55.2%
- Nov 5, 2026: Short sales 52.1%
- Nov 6, 2026: Short sales 53.5%
- Nov 9, 2026: Short sales 54.7%
- Nov 10, 2026: Short sales 44.7%
- Nov 11, 2026: Short sales 47.2%
- Nov 12, 2026: Short sales 60.7%
- Nov 13, 2026: Short sales 54.2%
- Nov 16, 2026: Short sales 65.2%
- Nov 17, 2026: Short sales 62.7%
- Nov 18, 2026: Short sales 60.4%
- Nov 19, 2026: Short sales 53.9%
- Nov 20, 2026: Short sales 45%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Mihael Hristos PolymeropoulosPresident and CEODirectly2.70M
- Gunther BirznieksSVP, Business DevelopmentDirectly494.2K
- Kevin Patrick MoranSVP, CFO & TreasurerDirectly411.4K
- Timothy WilliamsSVP & General CounselDirectly377.5K
- Joakim WijkstromSVP, Chief Marketing OfficerDirectly333.5K
- Richard W DuganDirectorDirectly219.1K
- Phaedra ChrousosDirectorDirectly165.0K
- Anne Sempowski WardDirectorDirectly160.7K
- Tage HonoreDirectorDirectly135.1K
- Stephen Ray MitchellDirectorDirectly112.8K
- Daniel Patrick McGuireSVP, GC and SecretaryDirectly110.0K
- Charles Cliff DuncanDirectorDirectly108.7K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Mihael Hristos PolymeropoulosPresident and CEO | 2.70M | – | Mar 2, 2026 | Form 4 |
| Gunther BirznieksSVP, Business Development | 494.2K | – | Mar 2, 2026 | Form 4 |
| Kevin Patrick MoranSVP, CFO & Treasurer | 411.4K | – | Mar 2, 2026 | Form 4 |
| Timothy WilliamsSVP & General Counsel | 377.5K | – | Mar 2, 2026 | Form 4 |
| Joakim WijkstromSVP, Chief Marketing Officer | 333.5K | – | Mar 2, 2026 | Form 4 |
| Richard W DuganDirector | 219.1K | – | Jun 4, 2026 | Form 4 |
| Phaedra ChrousosDirector | 165.0K | – | Jun 4, 2026 | Form 4 |
| Anne Sempowski WardDirector | 160.7K | – | Jun 4, 2026 | Form 4 |
| Tage HonoreDirector | 135.1K | – | Jun 4, 2026 | Form 4 |
| Stephen Ray MitchellDirector | 112.8K | – | Jun 4, 2026 | Form 4 |
| Daniel Patrick McGuireSVP, GC and Secretary | 110.0K | – | Jun 4, 2026 | Form 4 |
| Charles Cliff DuncanDirector | 108.7K | – | Nov 5, 2026 | Form 4 |
A lower bound: it counts only the 12 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.13%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.08%
- IWCiShares Micro-Cap ETFWeight in the fund0.07%
- IBBiShares Biotechnology ETFWeight in the fund0.03%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.02%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.01%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.01%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.01%
21 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 151
- Q4 2025: Managers 153
- Q1 2026: Managers 172
- Q2 2026: Managers 172
Institutional investors by quarter
The fund managers holding VNDA, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 172 managers held 49.68M shares, worth $304M. During the quarter 28 opened a position, 28 closed one, 66 added and 54 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+5.2%
- State StreetIn the quarter+17%
- AQR CapitalIn the quarter+118%
- Renaissance TechnologiesIn the quarter-8.5%
- Vanguard Capital ManagementIn the quarter+1.7%
- AIGH Capital ManagementIn the quarter-26%
- Acadian Asset ManagementIn the quarter+6.8%
- Dimensional Fund AdvisorsIn the quarter-2.5%
- Millennium Mgmt (Englander)In the quarter-15%
- Geode Capital ManagementIn the quarter+2.8%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 7.65M | +5.2% | $47M |
| State Street | 3.52M | +17% | $22M |
| AQR Capital | 3.50M | +118% | $21M |
| Renaissance Technologies | 3.44M | -8.5% | $21M |
| Vanguard Capital Management | 2.52M | +1.7% | $15M |
| AIGH Capital Management | 2.04M | -26% | $13M |
| Acadian Asset Management | 1.92M | +6.8% | $12M |
| Dimensional Fund Advisors | 1.73M | -2.5% | $11M |
| Millennium Mgmt (Englander) | 1.60M | -15% | $9.8M |
| Geode Capital Management | 1.48M | +2.8% | $9.1M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Vanda Pharmaceuticals's filings show?
Who buys and sells is one part of Vanda Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have VNDA's insiders bought or sold?
From Jun 8, 2026 to Nov 5, 2026 Vanda Pharmaceuticals's insiders bought $38.1K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold VNDA?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $21M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.